Commentaries

Commentary: Attack on the future

As part of a package commemorating the twentieth anniversary of 9/11, BioCentury is republishing this commentary, which was originally published on Sept. 17, 2001. BioCentury is also republishing its September...

Lisa Raines: An appreciation

As part of a package commemorating the twentieth anniversary of 9/11, BioCentury pays tribute to Lisa Raines, who helped build the biopharma industry’s regulatory and policy framework. BioCentury’s Sept....

Remembering Fred Frank, a giant of biotech

Fred is gone. A true giant of the biotechnology industry has left this world, but his imprint has not left the industry. Frederick Frank started his career on Wall Street after completing his MBA at...

A path forward on access & IP for COVID vaccines and beyond: Guest Commentary

An old African proverb states that if you want to go fast, go alone. But if you want to go far, go together. As the WTO Trips Council convenes to discuss access and patents in...

Industry and policymakers must embrace pragmatic drug pricing reforms: Guest Commentary

Simply wishing that drug pricing reforms won’t happen will only lead to draconian solutions imposed upon industry that undermine the long-term interests of the U.S. public and global health. The biotech...

FDA’s aducanumab decision will erode public trust: an Editor’s Commentary

In granting accelerated approval to aducanumab from Biogen, FDA has weakened the bonds of trust that are its greatest strength. The action doesn’t mean FDA will approve drugs based on post hoc statistical...

Why FDA, Biogen should be unusually transparent with aducanumab data: an Editor’s Commentary

FDA’s decision about Biogen’s aducanumab will be of profound importance to Alzheimer’s patients and their families, determining if they have access to the treatment and shaping the future of Alzheimer...

There is a better way — moving beyond the patents vs access debate: A Guest commentary

The debate about whether to suspend patent rights for COVID vaccines doesn’t need to be an “us vs. them” battle that pits access against innovation. Drawing on our previous work for Gilead, we propose a...

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

Years before the novel coronavirus began cutting its lethal course across nearly every continent on earth, scientists and senior executives at leading biopharmaceutical companies were discussing ways of accelerating the design, efficiency and pace of...

First-time CEOs must stop doing what made them successful: Guest Commentary

First-time CEOs of biotechs must not fall in the trap of continuing to excel in the domain areas their career success has been built on. Effectively stepping up to the chief executive role requires getting...

FDA should revamp its COVID-19 vaccine advisory committee meetings: Editor’s Commentary

One of the lessons from the COVID-19 experience is that influencing beliefs and actions is crucial for prevailing over a pandemic. Public health policies and medical countermeasures can only be implemented effectively if millions of...

What we must do to prepare for the next pandemic, a guest commentary

The U.S. is not ready for the next pandemic. Our public health infrastructure and planning process are not up to the challenge, our capacity to treat at-risk citizens is insufficient, and we are not making...

The U.S. needs a COVID commission: Editor’s Commentary

No country was better prepared for a pandemic than the United States and in no country has the response been as disastrously incompetent. The American public needs to know why. By the end of January,...

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...

Innovations forged in the COVID crucible will reshape medicine: Editor’s Commentary

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...